Florey Biosciences spins out of Harvard Wyss Institute to develop a medical food aimed at managing impacts of antibiotic use
The synthetic biology company engineers probiotics for human health, starting with a novel technology intended for the management of conditions associated with antibiotic treatment. Florey completed a pre-seed financing led by Seerave Ventures. Peter Barton Hutt, former Chief Counsel of FDA, and Mark B. Smith, co-founder of OpenBiome and Finch Therapeutics, joined Florey Board.